Sarcopenic Obesity and GLP-1 Therapy: Screening and Management in 2026
Sarcopenic obesity is underdiagnosed and changes GLP-1 risk profile. This article covers ESPEN/EASO criteria, screening tools, and modified protocols for at-risk patients.
GLP-1 Nutrition
Nutritional considerations during and after GLP-1 receptor agonist therapy. Topics include lean mass preservation, protein targeting, micronutrient screening, off-ramping protocols, and side-effect-aware portion guidance — written and reviewed by Registered Dietitians.
GLP-1 Side Effects and Food Aversions: What RDs Should Know in 2026
Practical guide to managing nausea, food aversions, taste changes, and reduced intake during GLP-1 therapy — symptom patterns, mitigation, and red flags for RDs.
Off-Ramping GLP-1 Medications: A 2026 Tapering Protocol
Discontinuation of GLP-1 therapy reverses 65-70% of weight loss in one year. This guide covers tapering schedules, intensified behavioral support, and weight regain mitigation.
Preventing Lean Mass Loss on GLP-1 Therapy: 2026 Evidence Update
Evidence-based protocol for protecting lean body mass during GLP-1 weight loss — protein dose, distribution, resistance training prescription, and monitoring tools.
Semaglutide and Tirzepatide: A Dietitian's 2026 Clinical Guide
Evidence-based dietitian guide to semaglutide and tirzepatide for weight management — mechanisms, dosing, nutritional risks, and protein/micronutrient strategies in 2026.
See also: our app rankings and head-to-head comparisons apply our scoring methodology to consumer nutrition tools relevant to GLP-1 Nutrition.